Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2 T cells activities after hematopoietic transplantation for blood malignancies. J Immunother Cancer. 2020;8(1).
Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma. Eur J Haematol. 2020.
Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020.
Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3(24):4312-4325.
First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clin Infect Dis. 2019..
Incidence, Risk Factors, Outcomes and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Effects of low-dose glucocorticoid prophylaxis on chronic GVHD and GVHD-free, relapse-free survival after haploidentical transplantation: long-term follow-up of a controlled, randomized open-label trial. Biol Blood Marrow Transplant. 2018.
Factors affecting the CD34(+) cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor. Transfus Apher Sci. 2016..
Increased type 1 immune response in the bone marrow immune microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016..
Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation. J Immunol Res. 2014;2014:631951..